THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

Main Article Content

Paul Richardson *
Jacob Laubach
Anuj Mahindra
Constantine Mitsiades
Robert Schlossman
Irene Ghobrial
Teru Hideshima
Noopur Raje
Nikhil Munshi
Kenneth Anderson
(*) Corresponding Author:
Paul Richardson | paul_richardson@dfci.harvard.edu

Abstract

Advances in therapies for younger patients with multiple myeloma have resulted in significant improvements in outcome over recent years, on the contrary the progress in treatments for elderly patients has remained more modest. Traditionally, patients   who are not eligible for transplantation, like the older patients,  have been treated with the combination of melphalan plus prednisone (MP), which leads to responses in approximately 50% of patients; however, patients rarely achieve a complete response (CR) and long-term outcomes are disappointing, with a relapse-free survival of approximately 18 months and an overall survival (OS) of approximately 3 years.

With the arrival of novel agents, including the first–in-class proteasome inhibitor, bortezomib, and the immunomodulatory agents, thalidomide and lenalidomide, a shift in the management of older patients and/or those not eligible for transplantation has taken place. Increasingly, novel agents are now being incorporated into therapy, based on the positive findings from clinical trials in this setting, and outcomes have improved accordingly.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

Author Biographies

Paul Richardson, Harvard Medical School, Boston, Massachusetts

Jerome Lipper Multiple Myeloma CenterDana-Farber Cancer Institute and Massachusetts General HospitalHarvard Medical School, Boston, Massachusetts 

Jacob Laubach, Harvard Medical School, Boston, Massachusetts

Jerome Lipper Multiple Myeloma CenterDana-Farber Cancer Institute and Massachusetts General HospitalHarvard Medical School, Boston, Massachusetts